Someit Sidhu Sells 51,728 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Zura Bio Price Performance

NASDAQ:ZURA opened at $3.62 on Friday. The company’s 50 day moving average is $3.69 and its 200-day moving average is $3.77. Zura Bio Limited has a 12 month low of $2.00 and a 12 month high of $7.22.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sell-side analysts forecast that Zura Bio Limited will post -0.53 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright started coverage on shares of Zura Bio in a research report on Thursday. They set a “neutral” rating and a $5.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Thursday, August 15th. Finally, Oppenheimer increased their target price on shares of Zura Bio from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Zura Bio presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Hedge Funds Weigh In On Zura Bio

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new stake in Zura Bio in the 2nd quarter valued at approximately $43,000. Renaissance Technologies LLC grew its stake in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Forefront Analytics LLC increased its position in Zura Bio by 46.8% during the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after acquiring an additional 6,765 shares during the period. Bank of New York Mellon Corp raised its stake in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares during the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in Zura Bio in the 1st quarter valued at $1,157,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.